Publications by authors named "Eiji Nishiyama"
Article Synopsis
- Nivolumab combined with chemotherapy has become the standard treatment for advanced HER2-negative gastric cancer, with a focus on understanding its long-term effects through clinical trials.
- In the ATTRACTON-4 trial, conducted across Japan, South Korea, and Taiwan, patients were assigned to either nivolumab or a placebo alongside common chemotherapy regimens, with the primary goals being progression-free survival and overall survival.
- After three years, the nivolumab group showed longer progression-free survival but similar overall survival compared to the placebo group, with a significant majority of patients who responded completely to treatment remaining alive, indicating its effective and safe use in this setting.
Article Synopsis
- This study analyzed changes in treatment patterns for Japanese patients with resectable gastric cancer from 2008 to 2022, focusing on adjuvant and recurrent therapy.
- In the adjuvant cohort, the use of S-1 decreased as new regimens were adopted, with S-1 making up 65% of treatments by 2019-2022, compared to 95.7% earlier.
- The recurrent cohort showed common first-line treatments like paclitaxel plus ramucirumab and S-1 combinations, aligning with Japanese Gastric Cancer Association guidelines.
Patients who have an ischemic stroke are at high risk of swallowing disorders. Aspiration due to swallowing disorders, specifically delayed trigger of the pharyngeal stage of swallowing, predisposes such patients to pneumonia. In the present study, we evaluated swallowing reflex in a rat model of transient middle cerebral artery occlusion (tMCAO), which is one of the most common experimental animal models of cerebral ischemia, in order to develop a novel animal model of dysphagia following ischemic stroke.
View Article and Find Full Text PDF